US4197288A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Neuroleptic radioreceptor assay method and kit
Assignee: SmithKline Beecham Corp
•
Filing: 1977-10-26
•
Granted: 1980-04-08
•
Expires: 1997-10-26
Abstract
Abstract Method, composition of matter and kit for determining the concentration of neuroleptic drug(s) in an animal or human patient's body fluid e.g., blood serum, blood plasma, urine, saliva, spinal fluid, etc., which comprises combining the patient's body fluid with dopamine receptor material and radioactive dopamine receptor binder and then measuring the percent inhibition of binding of the radioactive binder by the drug in the patient's fluid. The kit for performing the above method includes dopamine receptor material and radioactive dopamine receptor binder.
Inventors
- 👤 Solomon H. Snyder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 02:27
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/94; G01N33/9406; G01N33/9413; G01N2500/00; Y; Y10; Y10S; Y10S436/00; Y10S436/807; Y10S436/808
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
86 words
The method of determining the concentration of neuroleptic drug and any active metabolites thereof in a body fluid containing same comprising (a) mixing together dopamine receptor material, radioactive dopamine receptor binder and body fluid, and measuring the amount of the radioactive dopamine receptor binder on the dopamine receptor material and (b) mixing together a concentration of a standard amount of non-radioactive dopamine receptor binder, dopamine receptor material and radioactive dopamine receptor binder and measuring the amount of radioactive dopamine receptor binder or the dopamine receptor material.
Claim 2
Independent Claim
86 words
The method of determining the concentration of neuroleptic drug and any active metabolites thereof in a body fluid containing same comprising (a) mixing together dopamine receptor material, radioactive dopamine receptor binder and body fluid, and measuring the amount of the radioactive dopamine receptor binder on the dopamine receptor material and (b) mixing together a concentration of a standard amount of non-radioactive dopamine receptor binder, dopamine receptor material and radioactive dopamine receptor binder and measuring the amount of radioactive dopamine receptor binder or the dopamine receptor material.
Claim 3
Dependent Claim
48 words
The method of claim 1 in which the material, binder, and body fluid are permitted to remain together a time sufficient to produce sufficient binding of the binder and drug and any active metabolites thereof in the body fluid to said receptor material prior to making the measurement.
Claim 4
Dependent Claim
30 words
The method of claim 1 in which the material, binder and body fluid are combined in the presence of sufficient buffer to produce a pH of about 6 to 9.
Claim 5
Dependent Claim
19 words
The method of claim 1 in which unbound binder and body fluid are removed as part of the measurement.
Claim 6
Dependent Claim
27 words
The method of claim 1 in which the dopamine receptor material is brain tissue, and the radionuclide portion of the binder comprises 3 H or radioactive iodine.
Claim 7
Dependent Claim
14 words
The method of claim 1 in which iodine is 125 I or 131 I.
Claim 8
Dependent Claim
22 words
The method of claim 1 in which the concentration of body fluid in the mixture containing same is less than about 15%.
Claim 9
Dependent Claim
22 words
The method of claim 7 in which the concentration of body fluid in the mixture containing same is less than about 10%.
Claim 10
Dependent Claim
34 words
The method of claim 1 in which radioactive dopamine receptor binder is selected from the group of radioactive labelled, haloperidol, pimozide, chlorpromazine, fluphenazine, flupenthixol, spiroperidol, clazapine, thioridazine, fluspirilene, chopenthixol, loxapine, perphenazine, dopamine and apomorphine.
Claim 11
Dependent Claim
15 words
The method of claim 9 in which the radioactive receptor binder is radioactive labelled haloperidol.
Claim 12
Dependent Claim
15 words
The method of claim 9 in which the radioactive receptor binder is radioactive labelled spiroperidol.
Claim 13
Dependent Claim
42 words
The method of claim 1 in which measuring of the amount of radioactive dopamine receptor binder on the dopamine receptor material is determined in a gamma detector or scintillation counter based upon the nature of the radionuclide portion of the radioactive binder.
Claim 14
Dependent Claim
37 words
The method of claim 1 in which the concentration of drug and metabolite in the blood is determined by reference to a standard curve representing percent inhibition of radioactive dopamine receptor binder vs. non-radioactive dopamine receptor bind.
Claim 15
Dependent Claim
30 words
The method of claim 1 in which (b) is repeated a sufficient number of times while varying concentration of the non-radioactive binder to provide information for generating a standard curve.
Claim 16
Dependent Claim
17 words
The method of claim 14 in which the radioactive binder is the same in (a) and (b).
Claim 17
Dependent Claim
13 words
The method of claim 1 in which the receptor material is brain tissue.
Claim 18
Dependent Claim
16 words
The method of claim 1 in which the body fluid is blood plasma or blood serum.
Claim 19
Independent Claim
98 words
The method of measuring the concentration of neuroleptic drug and any active metabolites thereof in blood plasma or blood serum containing same which comprises (a) mixing together blood plasma or blood serum with radioactive dopamine receptor binder and dopamine receptor material and measuring the amount of the radioactive dopamine receptor binder on the dopamine receptor material and (b) mixing together a concentration of a standard amount of non-radioactive dopamine receptor binder, dopamine receptor material and the same radioactive dopamine receptor binder as in (a) and measuring the amount of radioactive dopamine receptor binder on the dopamine receptor material.
Claim 20
Independent Claim
98 words
The method of measuring the concentration of neuroleptic drug and any active metabolites thereof in blood plasma or blood serum containing same which comprises (a) mixing together blood plasma or blood serum with radioactive dopamine receptor binder and dopamine receptor material and measuring the amount of the radioactive dopamine receptor binder on the dopamine receptor material and (b) mixing together a concentration of a standard amount of non-radioactive dopamine receptor binder, dopamine receptor material and the same radioactive dopamine receptor binder as in (a) and measuring the amount of radioactive dopamine receptor binder on the dopamine receptor material.
Claim 21
Dependent Claim
42 words
The method of claim 18 in which measuring of the amount of radioactive dopamine receptor binder on the dopamine receptor material is determined in a gamma detector or scintillation counter based upon the nature of the radionuclide portion of the radioactive binder.
Claim 22
Dependent Claim
35 words
The method of claim 19 in which the concentration of drug and active metabolite is determined by reference to a standard curve representing percent inhibition of radioactive dopamine receptor binder vs. non-radioactive dopamine receptor binder.
Claim 23
Dependent Claim
27 words
The method of claim 18 in which unbound drug, unbound radioactive binder and plasma or serum are removed as part of determining the percent inhibition of binding.
Claim 24
Dependent Claim
22 words
The method of claim 18 in which the concentration of body fluid in the mixture containing same is less than about 15%.
Claim 25
Dependent Claim
14 words
The method of claim 22 in which the concentration is less than about 10%.
Claim 26
Dependent Claim
22 words
The method of claim 23 in which the amount of body fluid in the mixture containing same is greater than one microliter.
Claim 27
Dependent Claim
13 words
The method of claim 18 in which the receptor material is brain tissue.
Claim 28
Dependent Claim
30 words
The method of claim 18 in which (b) is repeated a sufficient number of times while varying concentration of the non-radioactive binder to provide information for generating a standard curve.
Claim 29
Dependent Claim
25 words
As a mercantile unit, a kit of at least one container of radioactive dopamine receptor binder, dopamine receptor material and standard non-radioactive dopamine receptor binder.
Claim 30
Dependent Claim
25 words
As a mercantile unit, a kit of at least one container of radioactive dopamine receptor binder, dopamine receptor material and standard non-radioactive dopamine receptor binder.
Claim 31
Dependent Claim
35 words
The kit of claim 27 in which the radioactive dopamine receptor binder is selected from the group consisting of radioactive labelled pimozide, chlorpromazine, fluphenazine, flupenthixol, spiroperidol, clozapine, thioridazine, trifluoperazine, fluspirilene, clopenthixol, loxapine, haloperidol, and perphenazine.
Claim 32
Dependent Claim
31 words
The kit of claim 28 in which said standard binder is selected from the group consisting of, pimozide chlorpromazine fluphenazine flupenthixol spiroperidol clozapine thioridazine trifluoperazine fluspirilene clopenthixol loxapine haloperidol and perphenazine.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-04-08 | 1983-10-08 | 1984-04-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-04-08 | 1987-10-08 | 1988-04-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-04-08 | 1991-10-08 | 1992-04-08 | $7700.00 | Window Closed / Lapsed |